ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1011

Use of the Shingrix Vaccine Among Patients with Inflammatory Arthritis and Risk of Cardiovascular Events Following Herpes Zoster
Abstract Number: 0494

Usefulness of the Neutrophil-to-Lymphocyte Ratio, the Platelet-to-Lymphocyte Ratio and the Systemic Immune Inflammatory Index in Assessing Disease Activity in Rheumatoid Arthritis Patients
Abstract Number: 0505

UseofaMolecularSignatureResponseClassifiertoPredictInadequateResponsetoTNFiResultsinFewer Patients Prescribed TNFi
Abstract Number: 0533

Using Adalimumab Serum Concentration to Choose a Subsequent DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment (ADDORA-switch): Results of a Blinded Randomized Test Treatment Trial
Abstract Number: 1294

Using Case-Based Continuing Education to Identify and Address Knowledge and Behavior Gaps in ANCA-associated Vasculitis
Abstract Number: 1662

Using Circulating Soluble Serum Mediator Profiles to Understand the Mechanisms Driving Disease Flare and Drug-free Remission in Rheumatoid Arthritis
Abstract Number: 0643

Using FDG PET Brain Scans and Deep Learning Analyses to Identify a Specific Network Correlated with Cognitive Impairment in SLE
Abstract Number: 0391

Using Machine Learning to Predict Inactive Disease in Juvenile Idiopathic Arthritis
Abstract Number: 1410

Using Social Listening to Understand the Patient Voice: The Daily Impacts of Sjögren’s Disease
Abstract Number: 1962

Utility of 18 FDG-PET/CT Scans in the Diagnosis of Polyarteritis Nodosa and Other Medium Vessel Vasculitis
Abstract Number: 1342

Utility of Anti-Carbamylated Antibodies in Early Rheumatoid Arthritis in South Asian Population
Abstract Number: 2382

Utility of Urinary Biomarkers to Predict Long-term Renal Outcomes in Lupus Nephritis
Abstract Number: 1061

Utilization of Electronic Health Record System to Improve Glucocorticoid Induced Osteoporosis Screening and Treatment
Abstract Number: PP16

Utilization of My Knee Notes for Enhanced Healthcare Management
Abstract Number: 1928

Utilization of Rapid Telehealth Visits by Advanced Practice Providers for New Patients Referred to a Large Academic Practice with Low Suspicion for Rheumatologic Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].